We performed whole exome sequence (WES) to identify genetic modifiers on 184 individuals with 22q11.2 deletion syndrome (22q11DS), of whom 89 case subjects had severe congenital heart disease (CHD) and 95 control subjects had normal hearts. Three genes including JMJD1C (jumonji domain containing 1C), RREB1 (Ras responsive element binding protein 1), and SEC24C (SEC24 family member C) had rare (MAF < 0.001) predicted deleterious single-nucleotide variations (rdSNVs) in seven case subjects and no control subjects (p ¼ 0.005; Fisher exact and permutation tests). Because JMJD1C and RREB1 are involved in chromatin modification, we investigated other histone modification genes. Eighteen case subjects (20%) had rdSNVs in four genes (JMJD1C, RREB1, MINA, KDM7A) all involved in demethylation of histones (H3K9, H3K27). Overall, rdSNVs were enriched in histone modifier genes that activate transcription (Fisher exact p ¼ 0.0004, permutations, p ¼ 0.0003, OR ¼ 5.16); however, rdSNVs in control subjects were not enriched. This implicates histone modification genes as influencing risk for CHD in presence of the deletion.
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The 22q11.2 deletion syndrome (22q11DS; DiGeorge syndrome/velo-cardio-facial syndrome [MIM: 192430, 188400] ) is a congenital malformation disorder that occurs in 1/4,000 live births. The affected individuals have a de novo, hemizygous 3 million base pair (Mb) deletion on chromosome 22q11.2. A total of 60%-70% have congenital heart disease (CHD), mostly of the conotruncal type. Among these, some have severe anomalies, such as tetralogy of Fallot (TOF) or persistent truncus arteriosus (PTA), while others have mild phenotypes such as isolated ventricular septal defects (VSD) or right-sided aortic arch. Haploinsufficiency of TBX1 (MIM: 602054), encoding a T-box transcription factor, is believed responsible for the etiology of CHD in 22q11DS. [1] [2] [3] A likely explanation for phenotypic heterogeneity of CHD would be the presence of mutations in TBX1 on the remaining 22q11.2 allele. However, causative second-hit mutations in TBX1 among 1,022 22q11DS-positive subjects were not found, 4 implicating other genes as being responsible, perhaps lying elsewhere in the genome. A common duplication of the glucose transporter gene SLC2A3 (MIM: 138170) was significantly enriched in 22q11DS-affected individuals with CHD, implicating this copy-number variation as a genetic modifier for some subjects. 5 However, this cannot explain the presence or absence of a heart or aortic arch defect in most other individuals with 22q11DS. Another possibility is that rare coding predicted deleterious single-nucleotide variants (rdSNVs) might act as modifiers of phenotype in 22q11DS. To search for rare coding variants, we ascertained 186 individuals with the typical 3 Mb, 22q11.2 deletion and extremes of cardiac phenotypes for a whole exome sequencing (WES) study. Echocardiography or cardiology reports were provided on each individual with their informed consent (Internal Review Board, 1999 . WES was performed with Nimblegen v.3 libraries (NHLBI, Resequencing Service) on DNA from blood and two samples were removed because they were duplicates, leaving 184 for the analysis. The average read depth for the targeted exome was 613, with 84% of the target regions covered at greater than 203. Finally, we compared data from 89 CHD-affected case subjects (mostly TOF) with 22q11DS and 95 deleted individuals with a normal heart and aortic arch (control subjects) to identify genes that harbor rare coding variants that could alter risk for extremes of heart phenotypes ( Figure 1A ). In addition, we evaluated ethnicity of the cohort via principal-component analysis and found all except two were of European descent ( Figure 1B) .
Among all 184 DNA samples, 411,618 variants including 370,551 SNVs and 41,067 indels were identified ( Figure S1 ). A total of 279,820 SNVs were retained after filtering on quality controls of genotype and SNVs depending upon the depth of sequencing reads. Most relevant to any phenotype are non-synonymous or splicing variants because they could impact the function of the protein. Figure S1 ). All 184 individuals have a similar size 3 million base pair (Mb) 22q11.2 deletion as determined by molecular testing. We first evaluated the overall genetic architecture of rdSNVs in the entire cohort of case and control subjects together. The rdSNVs were distributed among 10,620 genes, in which at least two individuals had rdSNVs in 5,431 genes. To reduce the noise of the enrichment analysis, we further selected genes based upon the residual variation intolerance score (RVIS) 8 and haploinsufficient score. 9 A total of 671 genes with rdSNVs in at least two 22q11DS-positive individuals were used to investigate the potential biological relevance of the affected genes (Functional Annotation Tool in DAVID, The Database for Annotation, Visualization and Integrated Discovery 10 ).
We used all the genes in the genome as background to calculate p values via the Fisher exact statistical test. Gene Ontology (GO) terms were considered significantly enriched with a Benjamini multiple test correction p value of < 0.05. We found significant enrichment in 58 ''biological process'' terms, 68 terms in ''cellular component,'' and 44 terms in ''molecular function'' (Table S1 ). The top three GO terms relate to chromosome organization or chromatin function (Figure 2A ). The GO terms related to ''organ development'' were also enriched ( Figure 2A ). To reduce the redundancy of GO terms from the enrichment analysis, we used the REVIGO tool, which uses a simple clustering algorithm to summarize GO terms.
11 GO terms were clustered into ''tissue development,'' ''chromosome organization,'' ''regulation of transcription,'' and ''RNA transport'' ( Figure 2B ). The genes related to chromosomeassociated GO terms might be involved in the etiology of the de novo deletion itself, while those involved in organ development could contribute to the phenotypic heterogeneity of 22q11DS. To determine whether there were genes that could alter risk for extremes of heart phenotypes in particular, rdSNVs among 5,431 genes in at least two individuals with 22q11DS were collapsed into a single gene burden score. Then the Fisher exact test was used to compare the burden score between 22q11DS-affected subjects with CHD (case subjects with severe heart defects) and 22q11DS subjects without CHD (control subjects). Further, single value permutations, in which case versus control status is permuted 10,000 times, were used to perform an association analysis on the genes. Results were considered statistically significant with a p value of < 0.05. We did not identify any genes on the remaining allele with rdSNVs in two or more case or control subjects (data not shown). All three genes had rdSNVs in seven different case subjects but none in control subjects ( Figure 3A ; Table S2 ). Among JMJD1C, RREB1, and SEC24C, 17 rdSNVs have been identified and affected 20 case subjects ( Figure 3B ; Table S2 ). One case subject has rdSNVs in both JMJD1C and RREB1 (see Figure 3B ). If we included all rare non-synonymous variants (MAF % 0.1%) irrespective as to whether they are predicted as damaging or not, there were two additional case subjects with variants in JMJD1C and one case subject for RREB1. JMJD1C had the strongest p value for CHD among all the genes (p ¼ 0.001; Figures 3A and 3B (B) Ethnicity of 22q11DS cohort. Principal components (PCs) were calculated for common variants in WES data from the 184 study subjects (black dots) and 1000 Genomes Project population dataset to check the ethnicity of the cohort. The majority of the cohort clustered with the European (EUR, yellow) population, but one had African (AFR, orange) ancestry and one subject had South Asian (SAS, pink) ancestry. Abbreviations are as follows: AMR, Admixed American; EAS, East Asian.
Jmjd1c is expressed in the pharyngeal apparatus and outflow tract region of the heart in mouse embryos at stage E10.5 ( Figure S3 ). All rare non-synonymous variants in JMJD1C and RREB1 were validated by Sanger sequencing ( Figure S2 ).
To assess whether individual rdSNVs might affect protein function, we examined the type of the variant and its location with respect to the known protein domain structure of the gene product ( Figure 3B ). There were ten rare SNVs in JMJD1C, which affected nine CHD-positive case subjects and none of the control subjects (Figures 3B and 3C; Table S3). Thus, one specific SNV affected two CHD-positive case subjects ( Figure 3B ). Among the ten variants, the p.Ser1429Leu (c.4286C>T) variant has been identified in dbSNP (rs201627592) and NHLBI ESP6500 with a MAF of 0.0005 in 6,132 genomes. None of the other nine have been reported in these databases. The frequency of SNVs were also determined from the Exome Aggregation Consortium (ExAC), which is based on exome sequencing data of 60,706 unrelated individuals from various diseasespecific and population genetic studies. The p.Ser1429Leu variant had a MAF of 0.0004 among 60,450 samples, whereas the p.His546Tyr (c.1636C>T) and p.His941Arg (c.2822A>G) variants have been reported in six and one person in ExAC, respectively. The JmjC domain is characteristic of the jumonji family of transcription factors and it might be involved in histone demethylation. 12 The p.His2466Tyr (c.7396C>T) variant is located within the JmjC domain and the p.Leu250fs (c.748_749delTT) variant could generate a truncated protein that would lack the JmjC domain ( Figure 3C ), suggesting that they might result in a loss-of-function mutation. The rest of the variants are not located within a known domain of the protein. There were seven rare missense variants in RREB1, which affected eight CHD-affected case subjects and none of the control subjects ( Figure 3B ; Table S3 ). Thus, one variant was present in two different unrelated case subjects. Among the seven variants, p.Gly344Val (c.1031G>T), p.Ile614Met (c.1842C>G), and p.Pro1064Leu (c.3191C>T) have been identified in dbSNP (rs114551633, rs146678576, and rs143874633) and NHLBI ESP 6500 with a MAF < 0.0006 among 6,132 samples. None of the four other missense variants have been reported in dbSNP, 1000 Genomes Project, or NHLBI ESP 6500 Exome sequence databases. The p.Pro295Leu (c.884C>T) and p.Gly621Arg (c.1861G>C) variants have been reported in one and three case subjects, respectively, among 60,706 individual genomes. The p.Pro1064Leu variant was present in two CHD-affected case subjects. This variant is located in a proline-rich domain, 13 but none of the other variants are located within a known functional domain of the protein ( Figure 3C ). SEC24C encodes a protein that is a coat component of COPII vesicles, which transport proteins from the endoplasmic reticulum to the Golgi [14] [15] [16] and is required for embryonic development. 17 There were four rdSNVs in SEC24C, which affected seven CHD-affected case subjects and none of the control subjects (Table S3) Table S1 .
(B) Interactive network of significant GO terms. A total of 671 genes had rdSNVs in two or more individuals, as well as a 25% high percentile score for residual variation intolerance score (RVIS) and haploinsufficient score combined. These are the top genes that would likely possess inactivating or gain-of-function mutations. The biological GO enrichment of the 671 genes using DAVID (The Database for Annotation, Visualization and Integrated Discovery) was evaluated. The ''Interactive graph'' of the enriched ''Biological Process'' GO terms (Benjamini multiple test correction p value < 0.05) was visualized with REViGO software. The shade of gray of the fill in the circles indicates user-provided p value, with the darkest shade representing the highest p value. Highly similar GO terms are linked by edges in the graph, where the gray line width indicates the degree of similarity.
The American Journal of Human Genetics 97, 1-9, December 3, 2015 3 candidate for 22q11DS, encodes a DNA binding transcription factor that interacts with the chromatin machinery. 21, 22 This implicates regulation of transcription as being an important consideration for affecting extremes of heart phenotypes in the background of the 22q11. 29 It is possible that expression of these genes could be influenced by chromatin modification.
Of interest, in a previous WES study of non-syndromic or non-deleted syndromic CHD, of unknown diagnoses, of all types including conotruncal defects, de novo mutations were found in histone-modification pathway genes expressed in the heart. 30 Based on this evidence, we then examined other genes in the histone modification pathway (PW:0001338; Pathway Portal of the Rat Genome Database 31 ) for rdSNVs. We tested whether rdSNVs could be identified in two or more case subjects or two or more control subjects (not in both case and control subjects).
We also included the histone modification-related genes, which were identified in the WES study of non-syndromic CHD-affected subjects. 30 Histones can be modified by several post-translational mechanisms resulting in either activation or suppression of gene expression. [32] [33] [34] [35] [36] There are three major mechanisms responsible for histone modifications: methylation, acetylation, and ubiquitination. There are well-characterized modification sites on specific histone proteins that alter chromatin structure in order to activate or repress transcription. These particular modifications form the epigenetic code, as shown in Figure 4A . We identified rdSNVs of interest in some of these genes, in either case or control subjects. One hypothesis is that genes with mutations in case subjects have the opposite function as genes with mutations in control subjects. Alternatively, genes in case versus control subjects might affect certain modifications, whether activating or repressing transcription, implicating gene dysregulation. Histone methylation is a complex epigenomic process whereby both the position of the targeted amino acid as well as the degree of methylation (mono-, di-, or trimethylation) affects the overall structure of chromatin and ultimately gene transcription. The histone-modifying genes identified in subjects with non-syndromic CHD, such as WDR5, MLL2 (also known as KMT2D), CHD7, KDM5A, KDM5B, and SMAD2, affect H3K4 and H3K27 methylation. 30 Methylation of lysine residues is catalyzed by histone methyltransferases, whereas the reverse reaction is catalyzed by histone demethylases ( Figure 4A ). We examined these genes in our cohort for rdSNVs. Among them, we identified rdSNVs in four genes affecting methylation (H3K4) in control and not case subjects: MEN1 A B C Figure 3 . Identification of rdSNVs in JMJD1C, RREB1, and SEC24C in CHDAffected Case Subject with 22q11DS (A) Burden test results for JMJD1C, RREB1, and SEC24C. We performed a burden test for genes with at least one rdSNV in two or more individuals. with rdSNVs that might affect acetylation, but in the opposite manner (Figure 4 54 and KAT6B (K(Lysine) acetyltransferase 6B [MIM: 605880]). 55 Monoubiquitination of nucleosome histone H2A at lysine 119 leads to gene repression or silencing, whereas deubiquitination leads to gene activation. [56] [57] [58] [59] Four case subjects were identified with rdSNVs in two genes that catalyze deubiquitination ( Figure 4A) 62 and CBX8 (chromobox homolog 8), 63 -suggesting that overall dysregulation could occur downstream of the deletion. Interestingly, genes involved in histone modification have been suggested to act as hub genes that could serve as modifiers of disease states or phenotypes in humans. 64 It is thus possible that histone modifications in context of the 22q11.2 deletion might have effects on embryonic development for which the heart is particularly vulnerable. We examined the expression level of the chromatin-modifying genes in existing gene expression profiling data from mouse or human embryos (Table S4) . Expression level was compared to housekeeping genes versus genes differentially expressed in various tissues. Among them, Jmjd1c has greater than average gene expression in all the relevant tissues of biological interest (Table S4 ). However, these findings need to be tested with future expression and functional studies of progenitor cells for the heart during embryonic development. We then performed the burden tests for the entire histone modification pathway. Rare mutations were not significantly enriched in either case or control subjects (p ¼ 0.82, OR ¼ 0.83 [0.34, 2.07]). However, histone modifications could activate (JMJD1C, MINA, KDM7A, RREB1, USP16, BAP1, BRD7, MEN1, and KMT2B) or repress (KDM5A, KDM5B, PRDM2, PRMT5, SIRT4, HUWE1, and CBX8) gene expression, making it necessary to consider biological functions for burden testing. After collapsing the rdSNVs in either group and then performing a gene burden test, we found that case subjects with rdSNVs are significantly enriched in genes within the group that acti Figure 4B , where we identified the variants in genes activating or repressing transcription depending upon which chromatin-modifying gene was likely to be involved. Each variant of interest from each individual case or control subject with 22q11DS is shown. Overall, these results suggest that extremes of heart phenotypes in the 22q11.2 deletion background might be modified by rdSNVs in genes for demethylation and deubiquitination of transcription repression histone marks such as H3K9 and H2Kun119, thereby generating hypotheses to be tested in cardiac progenitor cells or animal models in the future.
Mutations that are de novo events might not be tolerated and have a high likelihood that they could contribute to the etiology of disease. In a previous report, 30 de novo heterozygous mutations in histone-modifying genes were identified in association with risk for CHD. Here, we have a different hypothesis in that variants in genes identified here do not cause disease on their own, but they act as modifiers of phenotype, when combined with the 22q11.2 deletion. The heterozygous variants in histonemodification genes identified here, when combined with the 22q11.2 deletion, could affect embryonic development or heart formation in humans. Future functional studies would be required to determine their effects with or without loss of critical genes on 22q11.2 or in the presence of the deletion itself. The way in which they can affect function might be complicated to dissect, because histone modifications are inter-connected and they act in combination and/or sequentially to regulate transcription. [65] [66] [67] [68] Further, chromatin modification works in concert with tissue-specific as well as general transcription factors, which ultimately regulate gene expression. Nonetheless, when taken together, genes important in modifying gene expression could influence developmental fields or cardiac progenitor cells that alter development of the heart and are worthy of further investigation. Numerous statistical methods have been developed to test aggregate groups of rare variants for gene-based association to disease. [69] [70] [71] Association results depend on locus architecture, effect size, and functional variant filters as well as which statistical methods are used. 72 Here we focused on histone-modifier genes because the top genes identified by WES involved histone modification and, in addition, de novo mutations in this class of genes were identified in non-syndromic or undiagnosed syndromic CHD subjects. 30 It is possible that integration of such methods combined with a larger cohort of subjects will be required to fully dissect the genetic architecture of modifiers of 22q11DS.
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